What Researchers Did
Researchers evaluated the efficacy and toxicity of biological effective dose-based fractionated stereotactic radiation therapy (FSRT) in 299 patients with 573 brain metastases from non-small cell lung cancer (NSCLC).
What They Found
The local tumor control rates for 573 lesions at 6 and 12 months were high, at 96.3% and 94.5% respectively. The median overall survival was 17.1 months, with 6- and 12-month overall survival rates of 78.5% and 63.3%. Six patients (2%) experienced adverse effects.
What This Means for Canadian Patients
This study suggests that fractionated stereotactic radiation therapy (FSRT) could offer effective local control for Canadian patients with brain metastases from non-small cell lung cancer. Patients undergoing this treatment might expect significant local tumor control and improved survival outcomes.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada or with Canadian participants.
Study Limitations
A limitation of this study is its single-center, retrospective design, which may limit generalizability.